entertainment -WSS

entertainment

author：comprehensive 2025-09-06 04:30:38 - browse：1

Red blood cells flow in an artery biotech — coverage from STAT — Adobe

PHILADELPHIA — An investigational drug aimed at preventing strokes significantly reduced the risk of bleeding compared with a commonly used blood thinner for stroke prevention, showing potential to be a safer alternative for patients.

Among patients with atrial fibrillation, an abnormal heart rhythm that increases the risk of stroke, abelacimab, developed by Anthos Therapeutics, cut the overall risk of bleeding by 67% compared to rivaroxaban, the blood thinner sold as Xarelto by Janssen Pharmaceuticals.

The treatment, injected monthly, also reduced the risk of major bleeding events by 74% and gastrointestinal bleeding by 93%, according to Phase 2 results presented here Sunday at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： Novo Nordisk to buy Cardior, building up pipeline of heart drugs

WSS

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Diabetes management: Digital health tools fall short, study says

U.K. officials, researchers try to ease path for bespoke genetic treatments

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Surgeons perform first xenotransplant using CRISPR'd pig kidney

knowledge

entertainment

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

Biotech investment managers search for lucrative opportunities

Medical leaders decry Supreme Court decision on affirmative action

Pregnancy ages women, but effects reverse after delivery

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Diabetes management: Digital health tools fall short, study says

How to save PrEP access — and even expand it

A deep dive into Applied Therapeutics’ data, and questions on Cassava

Activists slam private health insurers over coverage restrictions

Novo Nordisk obesity pill bests Wegovy in early trial

focus

NEJM study link tiny plastics in blood vessels to heart problems

Chinese researcher claims birth of first gene

Amylyx ALS drug fails large clinical trial

Pfizer, Moderna say biotech, pharma drug development is a sprint

The problem with charging patients to message their doctors

Chinese researcher claims birth of first gene

explore

focus

Wikipedia

leisure time